New technology allowing a group of vehicles to exchange data automatically with each other and with traffic control centres could pave the way for a more efficient and safer European road network.

The Com2React team says their technology could be useful to drivers, traffic police, emergency services and companies with a fleet of vehicles to manage.

The researchers developed a system to help inform drivers of poor weather or road conditions immediately ahead, allowing them to choose alternate routes, easing congestion and cutting down on accidents, says Dr Chanan Gabay, Com2React’s (C2R) project coordinator.

Research carried out by scientists from Earthwatch, the international environmental charity, has reinforced the urgent need to protect Europe’s remaining peat bogs.

Dubbed the ‘rainforests of Europe’ as they are so diverse in wildlife, peat bogs contain more than 20 per cent of the world’s carbon. However, western Europe has lost most of its natural peat bogs, largely due to peat extraction for horticulture.

Doctors are adjusting their bedside manner as better informed patients make ever-increasing demands and expect to be listened to, and fully involved, in clinical decisions that directly affect their care.

You know, how doctors always said patients should be.

In a study just published in Clinical Orthopaedics and Related Research, Dr. J. Bohannon Mason of the Orthocarolina Hip and Knee Center in Charlotte, NC, USA, says changes in society, the population and technology are influencing the way patients view their orthopaedic surgeons. As patients gain knowledge, their attitude to medicine changes: They no longer show their doctors absolute and unquestionable respect.

WASHINGTON, February 16 /PRNewswire/ --

- President Praised for Creating PEPFAR; However, Proposed Changes in Priorities Cut Heart from Lifesaving Effort

A 40,000-year-old tooth has provided scientists with the first direct evidence that Neanderthals moved from place to place during their lifetimes.

In a collaborative project involving researchers from the Germany, the United Kingdom, and Greece, Professor Michael Richards of the Max Planck institute for Evolutionary Anthropology in Leipzig, Germany and Durham University, UK, and his team used laser technology to collect microscopic particles of enamel from the tooth.

Contrary to our previous beliefs, identical twins are not genetically identical. This surprising finding is presented by American, Swedish, and Dutch scientists in a study being published today in the prestigious journal American Journal of Human Genetics. The finding may be of great significance for research on hereditary diseases and for the development of new diagnostic methods.

How can it be that one identical twin might develop Parkinson’s disease, for instance, but not the other" Until now, the reasons have been sought in environmental factors. The current study complicates the picture.

For more than a decade, Peter Zandstra has been working at the University of Toronto to rev up the production of stem cells and their descendants. The raw materials are adult blood stem cells and embryonic stem cells. The end products are blood and heart cells – lots of them. Enough mouse heart cells that they form beating tissue.

BOSTON, February 15 /PRNewswire/ --

PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) notes the recent movement in the share price of ClinPhone plc ("ClinPhone" or the "Company"). Under the United Kingdom Takeover Code, PAREXEL confirms that it has made a preliminary proposal to the Board of ClinPhone in relation to a potential offer by PAREXEL for the entire issued and to be issued share capital of ClinPhone. While that preliminary proposal was rejected by the Board of ClinPhone, PAREXEL is currently evaluating its options in relation to ClinPhone. However, there can be no certainty that an offer for ClinPhone will be forthcoming.

Any offer, if made, is likely to be solely in cash. A further announcement will be made in due course.

ROCHESTER, New York, February 15 /PRNewswire/ --

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

HONG KONG, February 15 /PRNewswire/ --

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132).

The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a Genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5% at six months is highly acceptable when compared to published primary percutaneous coronary intervention (PCI) rates for bare metal stents. The paper also highlighted the low rate of major adverse cardiac events (MACE): 4.2% at 30 days and 5.8% at six months.